

# Impact of smoking on gums

<b>Submission date</b> 15/01/2015	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 04/02/2015	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 22/01/2019	<b>Condition category</b> Oral Health	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Cigarette smoking is one of the major risk factors for gum disease. The aim in this study is to assess the impact of cigarette smoking on healthy and diseased gum tissue.

### Who can participate?

Adult smokers and non-smokers

### What does the study involve?

Samples will be obtained of the fluid secreted where the gums meet the teeth.

### What are the possible benefits and risks of participating?

There are no known benefits to participants taking part in this study. There are no known risks to participants taking part in this study.

### Where is the study run from?

Ondokuz Mayıs University (Turkey)

### When is the study starting and how long is it expected to run for?

From September 2012 to March 2014

### Who is funding the study?

Ondokuz Mayıs University (Turkey)

### Who is the main contact?

Associate Professor Muge Lutfioglu

## Contact information

### Type(s)

Scientific

### Contact name

Dr Muge Lutfioglu

**ORCID ID**

<http://orcid.org/0000-0003-1499-5902>

**Contact details**

Ondokuz Mayıs University  
Dental Faculty  
Samsun  
Türkiye  
55139

**Additional identifiers**

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

**Secondary identifying numbers**

Ref No: B.30.2.ANK.0.21.63.00/824-02/9-8

**Study information****Scientific Title**

Interleukin 8 and lipoxin a4 levels in the gingival crevicular fluid of smokers and non-smokers with different periodontal diseases: a cross-sectional study

**Study objectives**

Investigate the effect of cigarette smoking on gingival crevicular fluid levels of interleukin 8 and lipoxin A4, cytokines that affect the polymorphonuclear functions in inflammatory response, in healthy individuals and those with periodontal disease because:

1. Cigarette smoking is one of the major risk factors for periodontal disease and has effects on the pathogenesis of the periodontal disease.
2. Smoking alters the host's response, including vascular function, neutrophil/monocyte activities, adhesion molecule expression, antibody production and cytokine and inflammatory mediator release.
3. Loss of proinflammatory mediators is the turn off signal for inflammation, ending subsequent responses passively
4. Resolution of inflammation and the return to homeostasis is an active and highly regulated biochemical process that is thought to be programmed at the tissue level.
5. Failure to remove the noxious products of smoking will have negative effects on cellular functions of the immune system and inflammatory cells might cause chronic and pathological lesions in healthy and diseased periodontal tissues.
6. Specialised immunoresolvents comprise endogeneous molecules including resolvins, lipoxins, protectins and maresins, which actively drive the termination of the inflammation.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Local ethics committee of the Dental School of Ankara University, 19/07/2011, reference number B.30.2.ANK.0.21.63.00/824-02/9-8

**Study design**

Cross-sectional observational study

**Primary study design**

Observational

**Secondary study design**

Cross sectional study

**Study setting(s)**

Hospital

**Study type(s)**

Other

**Participant information sheet**

A study population of smokers and nonsmokers was selected regarding the criteria: (i) to be  $\geq 18$  years of age and having  $\geq 16$  teeth, (ii) not to have previous periodontal therapy in the last 6 months, and (iii) not to have any systemic problems and regular/current (at least 6 weeks prior to data collection) chemotherapeutic regimens. Smoking status was determined as  $\geq 5$  years of duration and as  $\geq 15$  per day of consumption in all smokers, whereas non-smoking status included individuals who never smoked before.

**Health condition(s) or problem(s) studied**

Periodontal disease is a leucocyte-mediated inflammatory disease characterised by inflammation of the supporting tissues of the teeth induced by micro-organisms that stimulate the host immune and inflammatory responses.

**Interventions**

Gingival crevicular fluid samples will be obtained from the orifice of the gingival pocket, using commercially available periopaper strips for the assessment of:

1. Plaque index
2. Gingival index
3. Probing depth
4. Clinical attachment level
5. Bleeding on probing

**Intervention Type**

Other

**Primary outcome measure**

1. Silness and Loe plaque index
2. Loe and Silness gingival index
3. Probing pocket depth
4. Clinical attachment level
5. Bleeding on probing

Clinical measurements will be performed on six sites per tooth (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingua and, disto-lingual) using a Williams periodontal probe calibrated in millimetres on the patient's first visit to have periodontal treatment.

**Secondary outcome measures**

N/A

**Overall study start date**

01/09/2012

**Completion date**

30/03/2014

**Eligibility****Key inclusion criteria**

1. Smokers ( $\geq 5$  years of duration and  $\geq 15$  cigarettes per day)
2. Non-smokers (never smoked)
3. Age  $\geq 18$  years old
4.  $\geq 16$  teeth

**Participant type(s)**

Other

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

15 smokers and 15 non-smoker participants

**Key exclusion criteria**

1. History of cancer
2. History of rheumatoid arthritis
3. History of diabetes mellitus
4. History of cardiovascular diseases
5. Compromised immune system
6. Pregnancy
7. Menopause
8. Lactating
9. Ongoing drug therapy that may affect the clinical features of periodontitis
10. Systemic antimicrobials during the 6 weeks preceding the baseline examination
11. Any dental treatment during the past 6 months

**Date of first enrolment**

01/09/2012

**Date of final enrolment**

30/03/2014

## **Locations**

**Countries of recruitment**

Türkiye

**Study participating centre**

**Ondokuz Mayıs University**

Dental Faculty

Samsun

Türkiye

55139

## **Sponsor information**

**Organisation**

Ondokuz Mayıs University

**Sponsor details**

Dental Faculty

Samsun

Türkiye

55139

**Sponsor type**

University/education

**ROR**

<https://ror.org/028k5qw24>

## **Funder(s)**

**Funder type**

University/education

**Funder Name**

Ondokuz Mayıs University (Turkey)

# Results and Publications

## Publication and dissemination plan

Planning to send the manuscript for publication in March 2015

## Intention to publish date

31/03/2015

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Available on request

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/08/2016	22/01/2019	Yes	No